Creso Pharma Ltd (cph) Logo

Creso Pharma Ltd (CPH)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
SPONSORED

A Deep Dive profile provides ASX listed companies with an opportunity to tell their story in plain English.

Company Deep Dive

Creso was created to bring pharmaceutical expertise and methodological rigour to the world of cannabis and deliver quality products to people and animals everywhere.

Founded by a team of highly-experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.

Some notable achievements:

  1. The acquisition of Canadian psychedelics company Halucenex Life Sciences Inc. is now complete

  2. Creso is the first ASX listed psychedelics company which gives it a first mover advantage

  3. Psychedelic medicinal market estimated to be worth US $100bn by 2025

 

Showcase your ASX company to 500k+ investors

See Corporate Services

People

Board of Directors

Boaz Wachtel

Director & Co-Founder
Oct 2015 - Present

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company.

Profile

Boaz Wachtel

Director & Co-Founder

Oct 2015 - Present

Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland.

Adam Blumenthal

Non-Executive Chairman & Co-Founder
Oct 2015 - Present

Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies.

Profile

Adam Blumenthal

Non-Executive Chairman & Co-Founder

Oct 2015 - Present

Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.

Dr. James Ellingford

Executive Director
Oct 2015 - Present

Dr. Ellingford’s professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA.

Profile

Dr. James Ellingford

Executive Director

Oct 2015 - Present

Dr. Ellingford’s professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.

Executives and Strategic Advisors

Jorge Wernli

Commercial/Market Access Director
Oct 2016 - Present

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups.

Profile

Jorge Wernli

Commercial/Market Access Director

Oct 2016 - Present

Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.

Dr. Gian Trepp

Commercial/Marketing Director
Oct 2015 - Present

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership.

Profile

Dr. Gian Trepp

Commercial/Marketing Director

Oct 2015 - Present

Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.

Chris Hession

Director of Strategic Partnerships

Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region.

Profile

Chris Hession

Director of Strategic Partnerships

Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region. He has held leadership positions with a number of multi-national companies and introduced several new ingredients across the APAC region over this time.

Chris Grundy

Chief Financial Officer

Mr Grundy is a career CFO with over 30 years’ commercial experience in the life sciences sector, in listed and large multi- national companies as well as early-stage, rapidly-growing businesses.

Profile

Chris Grundy

Chief Financial Officer

Mr Grundy is a career CFO with over 30 years’ commercial experience in the life sciences sector, in listed and large multi- national companies as well as early-stage, rapidly-growing businesses. His experience in other companies includes operational roles in pharmaceutical manufacturing and distribution as CEO and in marketing. He has worked in Australia, the UK and Southern Africa. He qualified as a Chartered Accountant with Ernst & Young.

Bruce Linton

Strategic Advisor

Mr. Linton is one of the world’s leading cannabis executives and an accomplished entrepreneur. He has extensive sector experience as a founder, CEO, Board member and adviser to a number of global cannabis companies.

Key Monetisation Avenues

New Products

Psychedelic Medicines

Creso Pharma recently completed its acquisition of Canadian psychedelics company Halucenex Life Sciences Inc. This landmark acquisition makes Creso the first ASX listed psychedelics company and provides a first mover advantage into the psychedelic medicine sector. In the near term, Halucenex will focus on progressing clinical trials to assess the safety and efficacy of using psilocybin to treat mental illness, with the aim of becoming a clinical drug pipeline provider. The company has already secured sufficient psilocybin to take the company up to conclusion of its Phase 3 Trial (March 2023), and will progress its Clinical Trial Application next month.

  • Psychedelic medicinal market estimated to be worth US $100bn by 2025

 

Learn More
Creso and Halucenex logos
Psilocybin molecule
Solving

Psychedelics to Assist Mental Health

Studies have shown that psychedelics may be able to treat disorders such as depression, anxiety, and substance addiction. In clinical treatments, a patient receives a “microdose” of psilocybin to trigger the drug’s therapeutic benefits, without the disruptive effects seen at higher doses, such as hallucinations. The potential for psychedelic-assisted therapy to be commercialised as a safe and effective treatment provides a solution to the growing global mental health crisis.

Learn More
New Markets

California's "Bill SB 519" to Decriminalise Psychedelics

California has 39.5 million citizens. Bill SB 39 recently passed the State Assembly committee on Public Safety, and California is on track to become the second US state to legalise the use of psychedelics. If Bill SB 519 passes, the use and possession of psilocybin products will become legal.

  • This will be a positive result for Creso Pharma and Halucenex.

 

Map of California Population
Product Pipeline
Established Products

Medicinal Cannabis

Creso's goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company can deliver products with standardized dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.

  • The product pipeline is extensive, with 2020 Q4 set to see a range of new products hit the market

 

Progressive Law Changes

USA Progressing Towards Federal Cannabis Legalisation

Legislation was introduced on 15 July to remove cannabis from the Controlled Substances Act and introduce regulations to tax cannabis. The Act allows cannabis companies to use the federal banking system. Creso has been preparing for the legislation for quite some time, getting its CBD products ready to enter US. Their 24,000 Square foot cultivation facility (“Mernova”) in Canada is located only 220 miles from the US border.

  • The US cannabis market is expected to reach a valuation of US$41Bn by 2024.

 

US Senator

Key Milestones

Past Achievements

Successfully entered the Canadian, Swiss, APAC and Latin America markets
Launched a broad suite of cannabis products across 4 categories
Acquired Halucenex Life Sciences Inc making it the first ASX-listed psychedelics company

Upcoming Milestones

Halucenex to progress Clinical Trial Application
Pursuing a dual ASX and NASDAQ Listing

Investors and Capital Raises

Key Investors

S3 Consortium

BACKGROUND

Also known as “Stocks Digital”

Capital Raises

Placement - Firm Commitments
|Feb 2021

To undertake psychedelic clinical trials upon completion of the Halucenex transaction, and advance of nutraceutical products globally.

Raised $18m
Offer Price $0.19
Notes
Placement - Firm Commitments
|Sep 2020

From institutional, professional, and sophisticated investors to repay debt, develop the Company’s business units in Canada and Switzerland, and accelerate growth.

Raised $8.992m
Offer Price $0.0291
Notes
Placement - Firm Commitments
|May 2020

From new and existing sophisticated and professional investors to accelerate growth across the human and animal health CBD product line.

Raised $2.137m
Offer Price $0.06
Notes

Reports and Media

Presentation

03 Feb 2022 | Announcement
PDF (4620.1 KB)

December Quarterly Activities Report

31 Jan 2022 | Report
PDF (364.1 KB)

CPH Annual Report 2020

09 Mar 2021 | Report
PDF (1352.2 KB)

Add CPH to your Watchlist